Early ZEVASKYN Launch Traction and Robust Reimbursement Support Abeona Buy Rating and $20 Target

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Abeona Therapeutics today and set a price target of $20.00.

Ram Selvaraju has given his Buy rating due to a combination of factors tied to the early commercial progress of ZEVASKYN and the underlying demand profile. He points to the resumption of manufacturing, the completion of additional patient treatments, and a growing queue of biopsies and manufacturing runs as evidence that the U.S. launch is gaining traction, supported by strong interest from RDEB patients and families for a high-value therapy priced at roughly $3.1M per course.

Ram Selvaraju’s rating is based on expectations that the network of qualified treatment centers will expand and support rising monthly patient volumes, which should push Abeona toward cash-flow positivity despite a tempered near-term revenue forecast. He also highlights broad reimbursement coverage, including major commercial insurers, all Medicaid programs, and the assignment of a permanent J-code by CMS, which collectively reduce market-access risk and reinforce the long-term earnings potential that underpins his $20 twelve-month price target.

In another report released on February 23, Cantor Fitzgerald also maintained a Buy rating on the stock with a $28.00 price target.

Based on the recent corporate insider activity of 49 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ABEO in relation to earlier this year.